Benjamin M. Parsons

4.6k total citations
36 papers, 440 citations indexed

About

Benjamin M. Parsons is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Benjamin M. Parsons has authored 36 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 12 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Benjamin M. Parsons's work include Lymphoma Diagnosis and Treatment (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Breast Cancer Treatment Studies (6 papers). Benjamin M. Parsons is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Breast Cancer Treatment Studies (6 papers). Benjamin M. Parsons collaborates with scholars based in United States. Benjamin M. Parsons's co-authors include Andrew J. Borgert, Chadi Nabhan, Scott E. Smith, Annette K. Larsen, Stephanie Gregory, Reem Karmali, Andrew M. Evens, Erika Ramsdale, Britt Hanson and Sonali M. Smith and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Benjamin M. Parsons

29 papers receiving 432 citations

Peers

Countries citing papers authored by Benjamin M. Parsons

Since Specialization

Citations

This map shows the geographic impact of Benjamin M. Parsons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin M. Parsons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin M. Parsons more than expected).

Fields of papers citing papers by Benjamin M. Parsons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin M. Parsons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin M. Parsons. The network helps show where Benjamin M. Parsons may publish in the future.

Co-authorship network of co-authors of Benjamin M. Parsons

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin M. Parsons. A scholar is included among the top collaborators of Benjamin M. Parsons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin M. Parsons. Benjamin M. Parsons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CN13 Impact of AI clinical trial program on screening, matching, and enrollment of patients over 6 months 2024 ·Annals of Oncology ·(unknown), (unknown), (unknown), Donal Skelly, (unknown), Matthias Weiss, Bert H. O’Neil, Arvind Rao, (unknown), (unknown), Kamalesh K. Sankhala, Michael G. Goldstein, Benjamin M. Parsons, (unknown), (unknown), Eric P. Cohen, Marie Therese Cooney	0
2	Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion–Mutated Breast Cancer 2023 ·JCO Precision Oncology ·(unknown), (unknown), Dustin A. Deming, Mark E. Burkard, Paraic A. Kenny, Craig S. Richmond, Benjamin M. Parsons	2
3	Efficacy of HS-10382 (TERN-701) in tumor xenograft models, a new investigational allosteric ABL1 kinase inhibitor as a potential treatment for CML 2023 ·Journal of Pharmacology and Experimental Therapeutics ·Yuanfeng Zhou, Benjamin M. Parsons, Danni Sun, (unknown), Guoliang Chen, Mingjie Luo, Christopher J. Jones, (unknown), Xiaolei Wang, Yundong Sun, (unknown), Huifeng Niu	1
4	CML-593 The Novel BCR::ABL1 Allosteric Inhibitor HS-10382/TERN-701 is Potent Against Mutations Resistant to Active Site Tyrosine Kinase Inhibitors (TKIs) and Acts Synergistically With TKIs in BCR::ABL1+ Cancer Cell Lines 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Benjamin M. Parsons, Christopher J. Jones, Danni Sun, (unknown), (unknown), Xiaolei Wang, Yundong Sun, Yuanfeng Zhou, (unknown)	0
5	Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer 2020 ·Clinical Breast Cancer ·Benjamin M. Parsons, (unknown), Craig S. Richmond, Grzegorz T. Gurda, Kristopher A. Lofgren, Mark E. Burkard, Dustin A. Deming, Paraic A. Kenny	11
6	Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. 2020 ·Journal of Clinical Oncology ·Shaji Kumar, Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, (unknown), Terri L. Parker, Alex R. Menter, Xuezhong Yang, Benjamin M. Parsons, Pankaj Kumar, Prashant Kapoor, Aaron S. Rosenberg, Jeffrey A. Zonder, Edward A. Faber, Sagar Lonial, Paul G. Richardson, Robert Z. Orlowski, Lynne I. Wagner, S. Vincent Rajkumar	21
7	A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score–Matched Update From the National Cancer Data Base (NCDB) 2019 ·Clinical Breast Cancer ·Jeffrey Landercasper, Luis D. Ramirez, Andrew J. Borgert, (unknown), Benjamin M. Parsons, Leah L. Dietrich, Jared H. Linebarger	21
8	Utilization of Surgery and Its Impact on Survival in Patients With Early Stage Small-cell Lung Cancer in the United States 2019 ·Clinical Lung Cancer ·Dipesh Uprety, (unknown), (unknown), (unknown), Andrew J. Borgert, (unknown), Benjamin M. Parsons	19
9	Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma 2019 ·Experimental and Molecular Pathology ·Craig S. Richmond, (unknown), (unknown), (unknown), Benjamin M. Parsons, Paraic A. Kenny	8
10	Abstract 1317: Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations 2019 ·Cancer Research ·Benjamin M. Parsons, (unknown), Sreeja Sreekumar, Craig S. Richmond, (unknown), Kristopher A. Lofgren, (unknown), Grzegorz T. Gurda, Paraic A. Kenny	2
11	Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study 2019 ·Blood ·Craig A. Portell, N. Nora Bennani, Opeyemi A. Jegede, Seema Naik, Benjamin M. Parsons, Priyank Patel, Christopher M. Reynolds, Brad S. Kahl	3
12	A US Registry–Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer 2018 ·Journal of the National Comprehensive Cancer Network ·Benjamin M. Parsons, Dipesh Uprety, Angela Smith, Andrew J. Borgert, Leah L. Dietrich	12
13	Fewer Reoperations After Lumpectomy for Breast Cancer with Neoadjuvant Rather than Adjuvant Chemotherapy: A Report from the National Cancer Database 2017 ·Annals of Surgical Oncology ·Jeffrey Landercasper, (unknown), Benjamin M. Parsons, Leah L. Dietrich, Caprice C. Greenberg, Lee G. Wilke, Jared H. Linebarger	17
14	Exceptional Response to Crizotinib in an MET-Amplified Triple-Negative Breast Tumor 2017 ·JCO Precision Oncology ·Benjamin M. Parsons, (unknown), Grzegorz T. Gurda, Kristopher A. Lofgren, Paraic A. Kenny	5
15	21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013 2016 ·Breast Cancer Research and Treatment ·Benjamin M. Parsons, Jeffrey Landercasper, Angela Smith, Ronald S. Go, Andrew J. Borgert, Leah L. Dietrich	17
16	Anaplastic Large Cell Lymphoma of the Breast: Incidence, Patterns of Care, and Outcome in the US Population 2015 ·Blood ·(unknown), Ronald S. Go, Benjamin M. Parsons, Mohammed Al‐Hamadani	1
17	Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era 2011 ·Blood ·Andrew M. Evens, Irene Helenowski, Chadi Nabhan, Erika Ramsdale, June M. McKoy, Annette K. Larsen, (unknown), Benjamin M. Parsons, Reem Karmali, Britt Hanson, Leo I. Gordon, Scott E. Smith, Stephanie A. Gregory, (unknown), (unknown)	0
18	Analysis of very elderly (≥80 years) non‐hodgkin lymphoma: impact of functional status and co‐morbidities on outcome 2011 ·British Journal of Haematology ·Chadi Nabhan, Sonali M. Smith, Irene Helenowski, Erika Ramsdale, Benjamin M. Parsons, Reem Karmali, Josephine Feliciano, Britt Hanson, Scott E. Smith, June M. McKoy, Annette K. Larsen, Andrew Hantel, Stephanie Gregory, Andrew M. Evens	77
19	Novel approaches and future directions in castration-resistant prostate cancer 2011 ·Annals of Oncology ·Chadi Nabhan, Benjamin M. Parsons, (unknown), Walter M. Stadler	16
20	Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival 2010 ·Blood ·Andrew M. Evens, Chadi Nabhan, Irene Helenowski, Annette K. Larsen, Erika Ramsdale, Reem Karmali, Josephine Feliciano, Benjamin M. Parsons, June M. McKoy, Stephanie A. Gregory, Sonali M. Smith	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact